氯胺酮与依托咪酯作为危重成人气管插管诱导剂比较:贝叶斯Meta分析
该贝叶斯Meta分析检索MEDLINE、Embase和Cochrane Library(建库至2023年4月27日),纳入7项随机对照试验和1项倾向性匹配观察性研究,共2978例危重成人,比较氯胺酮与依托咪酯作为气管插管诱导剂。主要终点为最长随访死亡率:氯胺酮组376/1475(25%)vs 依托咪酯组411/1503(27%),RR 0.93(95%CrI 0.79-1.08),氯胺酮降低死亡风险的概率为83.2%,排除高偏倚风险研究的亚组分析结果一致。所有次要终点(SOFA评分、28天无呼吸机天数、28天无血管活性药天数、诱导后平均动脉压、首次插管成功率)均无显著差异。
要点
- 纳入7项RCT和1项倾向性匹配研究共2978例危重成人,对照药均为依托咪酯。
- 氯胺酮组死亡率376/1475(25%)vs 依托咪酯组411/1503(27%),RR 0.93(95%CrI 0.79-1.08)。
- 氯胺酮降低死亡风险的概率为83.2%,但95%可信区间跨1,未达统计学显著。
- 排除高偏倚风险研究的亚组分析结果与主分析一致。
- SOFA评分、28天无呼吸机天数、28天无血管活性药天数、诱导后平均动脉压、首次插管成功率均无显著差异。
适用人群与场景
- 危重成人,需行气管插管者(纳入随机对照试验和匹配观察性研究的人群)。
研究设计与关键结果
- 研究设计:贝叶斯随机效应Meta分析,纳入7项随机对照试验和1项倾向性匹配研究,共2978例患者;对照药均为依托咪酯。
- 主要终点(最长随访死亡率):氯胺酮组376/1475(25%)vs 依托咪酯组411/1503(27%),RR 0.93(95%CrI 0.79-1.08),氯胺酮降低死亡风险的概率为83.2%。
- 排除高偏倚风险研究的亚组分析结果与主分析一致。
- 次要终点(SOFA评分、28天无呼吸机天数、28天无血管活性药天数、诱导后平均动脉压、首次插管成功率)均无显著差异。
证据类型、等级与局限
- 证据类型:贝叶斯随机效应Meta分析(纳入随机对照试验和匹配观察性研究)。
- 局限:原文未报告局限性。
对床旁实践的改变
- 在危重成人气管插管诱导中,氯胺酮与依托咪酯相比,降低死亡风险的概率为83.2%,但未达统计学显著,原文未据此给出推荐。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Tracheal intubation is a high-risk intervention commonly performed in critically ill patients. Due to its favorable cardiovascular profile, ketamine is considered less likely to compromise clinical outcomes. This meta-analysis aimed to assess whether ketamine, compared with other agents, reduces mortality in critically ill patients undergoing intubation.
METHODS: We searched MEDLINE, Embase, and the Cochrane Library from inception until April 27, 2023, for randomized controlled trials and matched observational studies comparing ketamine with any control in critically ill patients as an induction agent. The primary outcome was mortality at the longest follow-up available, and the secondary outcomes included Sequential Organ Failure Assessment score, ventilator-free days at day 28, vasopressor-free days at day 28, post-induction mean arterial pressure, and successful intubation on the first attempt. For the primary outcome, we used a Bayesian random-effects meta-analysis on the risk ratio (RR) scale with a weakly informative neutral prior corresponding to a mean estimate of no difference with 95% probability; the estimated effect size will fall between a relative risk of 0.25 and 4. The RR and 95% credible interval (CrI) were used to estimate the probability of mortality reduction (RR < 1). The secondary outcomes were assessed with a frequentist random-effects model. We registered this study in Open Science Framework ( https://osf.io/2vf79/ ).
RESULTS: We included seven randomized trials and one propensity-matched study totaling 2978 patients. Etomidate was the comparator in all the identified studies. The probability that ketamine reduced mortality was 83.2% (376/1475 [25%] vs. 411/1503 [27%]; RR, 0.93; 95% CrI, 0.79-1.08), which was confirmed by a subgroup analysis excluding studies with a high risk of bias. No significant difference was observed in any secondary outcomes.
CONCLUSIONS: All of the included studies evaluated ketamine versus etomidate among critically ill adults requiring tracheal intubation. This meta-analysis showed a moderate probability that induction with ketamine is associated with a reduced risk of mortality.
参考来源
- Koroki T, Kotani Y, Yaguchi T, et al. Ketamine versus etomidate as an induction agent for tracheal intubation in critically ill adults: a Bayesian meta-analysis. Crit Care. 2024. PMID: 38368326. doi:10.1186/s13054-024-04831-4
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。